Acadian Asset Management LLC Crispr Therapeutics Ag Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$79.67 - $173.23 $50,431 - $109,654	-633 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$78.5 - $100.64 $670,468 - $859,566	-8,541 Reduced 93.1%	633 $53,000
Q2 2020 Aug 12, 2020	SELL	$38.5 - $76.05 $5.28 Million - $10.4 Million	-137,092 Reduced 93.73%	9,174 $674,000
Q1 2020 May 11, 2020	BUY	$33.68 - $62.53 $4.93 Million - $9.15 Million	146,266 New	146,266 $6.2 Million
Q2 2018 Jul 24, 2018	SELL	$42.62 - $73.59 $4,730 - $8,168	-111 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$23.52 - $58.17 $2,610 - $6,456	111 New	111 $5,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.